Answers are grounded in this paper and cite their sources.
Tailored inhibitors improve NAD+ binding disruption in sirtuin 2, suggesting advances in pharmaceutical therapy.
Human sirtuin 2 (SIRT2) is an NAD+ dependant enzyme that has been linked to the pathogenesis of various diseases, making it a promising target for pharmaceutical intervention. This study presents...
No takes yet. Share an insight, caveat, or question.
Wirawan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: